SLXN•benzinga•
Silexion Therapeutics Reports Groundbreaking Initial Data From Systemic Administration Of SIL204 In Orthotopic Pancreatic Cancer Models Demonstrating That Subcutaneously Administered SIL204 Effectively Reduces Both Primary Tumor Growth And Metastatic Spr
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 5, 2025 by benzinga